Discounted Cash Flow (DCF) Analysis Unlevered

Black Diamond Therapeutics, Inc. (BDTX)

$2.88

+0.01 (+0.35%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2.88 | undervalue

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2.88
Beta 2.469
Diluted Shares Outstanding 36.33
Cost of Debt
Tax Rate 4.95
After-tax Cost of Debt -13.20%
Risk-Free Rate
Market Risk Premium
Cost of Equity 16.278
Total Debt 28.14
Total Equity 104.62
Total Capital 132.76
Debt Weighting 21.20
Equity Weighting 78.80
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%-16.69%2.64%1.91%4.95%-1.44%-1.44%-1.44%-1.44%-1.44%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.08-0.02-0.14-2.71-0.19-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.03
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -6.17
Equity Value -
Shares Outstanding 36.33
Equity Value Per Share -